期刊
JOURNAL OF LIPID RESEARCH
卷 52, 期 2, 页码 189-206出版社
ELSEVIER
DOI: 10.1194/jlr.R009720
关键词
hypertriglyceridemia; hypotriglyceridemia; dyslipidemias; genetic variation; genomics; lipoproteins; resequencing
资金
- Canadian Institutes of Health Research (CIHR) [MOP-13430, MOP-79523, CTP-79853]
- Heart and Stroke Foundation of Ontario [NA-6059, T-6018, PRG-4854]
- Pfizer
- Genome Canada through the Ontario Genomics Institute
Plasma triglyceride (TG) concentration is re-emerging as an important cardiovascular disease risk factor. More complete understanding of the genes and variants that modulate plasma TG should enable development of markers for risk prediction, diagnosis, prognosis, and response to therapies and might help specify new directions for therapeutic interventions. Recent genome-wide association studies (GWAS) have identified both known and novel loci associated with plasma TG concentration. However, genetic variation at these loci explains only similar to 10% of overall TG variation within the population. As the GWAS approach may be reaching its limit for discovering genetic determinants of TG, alternative genetic strategies, such as rare variant sequencing studies and evaluation of animal models, may provide complementary information to flesh out knowledge of clinically and biologically important pathways in TG metabolism. Herein, we review genes recently implicated in TG metabolism and describe how some of these genes likely modulate plasma TG concentration. We also discuss lessons regarding plasma TG metabolism learned from various genomic and genetic experimental approaches. Treatment of patients with moderate to severe hypertriglyceridemia with existing therapies is often challenging; thus, gene products and pathways found in recent genetic research studies provide hope for development of more effective clinical strategies.-Johansen, C. T., S. Kathiresan, and R. A. Hegele. Genetic determinants of plasma triglycerides. J. Lipid Res. 2011. 52: 189-206.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据